RHAMM and CD44 peptides-analytic tools and potential drugs

Frontiers in Bioscience

Volumn 17, Issue 5, 2012, Pages 1775-1794

  Turley, Eva A ^a   Naor, David ^b  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b HEBREW UNIVERSITY   (Israel)

Author keywords

Arthritis; CD44 peptides; Peptide therapeutic potential; Polysaccharide hyaluronan; Review; RHAMM peptides

Indexed keywords

HERMES ANTIGEN; HYALURONAN MEDIATED MOTILITY RECEPTOR; HYALURONAN-MEDIATED MOTILITY RECEPTOR; SCLEROPROTEIN;

CHEMISTRY; DRUG EFFECT; METABOLISM; REVIEW; STRUCTURE ACTIVITY RELATION;

ANTIGENS, CD44; EXTRACELLULAR MATRIX PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84859258205     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4018     Document Type: Review

References (126)

1. J Jiang, R Casalegno-Garduno, H Chen, A Schmitt, M Schmitt, CA Maxwell: Multifunctional proteins bridge mitosis with motility and cancer with inflammation and arthritis. ScientificWorldJournal 10, 1244-1257 (2010).
2. CA Maxwell, J McCarthy, E Turley: Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J Cell Sci 121, 925-932 (2008). (Pubitemid 351639411)
3. D Naor, S Nedvetzki, M Walmsley, A Yayon, EA Turley, I Golan, D Caspi, LE Sebban, Y Zick, T Garin, D Karussis, N Assayag-Asherie, I Raz, L Weiss, S Slavin, I Golan: CD44 involvement in autoimmune inflammations: the lesson to be learned from CD44- targeting by antibody or from knockout mice. Ann N Y Acad Sci 1110, 233-247 (2007). (Pubitemid 350043012)
4. C Tolg, SR Hamilton, KA Nakrieko, F Kooshesh, P Walton, JB McCarthy, MJ Bissell, EA Turley: Rhamm-/- fibroblasts are defective in CD44-mediated ERK1, 2 motogenic signaling, leading to defective skin wound repair. J Cell Biol 175, 1017-1028 (2006). (Pubitemid 44969206)
5. S Nedvetzki, E Gonen, N Assayag, R Reich, RO Williams, RL Thurmond, JF Huang, BA Neudecker, FS Wang, EA Turley, D Naor: RHAMM, a receptor for hyaluronan-mediated motility, compensates for CD44 in inflamed CD44-knockout mice: a different interpretation of redundancy. Proc Natl Acad Sci USA 101, 18081-18086 (2004). (Pubitemid 40054077)
6. SR Hamilton, SF Fard, FF Paiwand, C Tolg, M Veiseh, C Wang, JB McCarthy, MJ Bissell, J Koropatnick, EA Turley: The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1, 2 that sustain high basal motility in breast cancer cells. J Biol Chem 282, 16667-16680 (2007). (Pubitemid 47100370)
7. S Misra, P Heldin, VC Hascall, NK Karamanos, SS Skandalis, RR Markwald, S Ghatak S: HA/CD44 interactions as potential targets for cancer therapy. FEBS J doi: 10.1111/j.1742-4658.2011.08071.x. (2011).
8. BP Toole: Hyaluronan-CD44 Interactions in Cancer: Paradoxes and Possibilities. Clin Cancer Res 15, 7462- 7468 (2009).
9. J Greiner, L Bullinger, BA Guinn, H Döhner, M Schmitt: Leukemia-associated antigens are critical for the proliferation of acute myeloid leukemia cells. Clin Cancer Res 14, 7161-7166 (2008).
10. S Adamia, CA Maxwell, LM Pilarski: Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord 5, 3-14 (2005). (Pubitemid 40246722)
11. KK Mantripragada, G Spurlock, L Kluwe, N Chuzhanova, RE Ferner, IM Frayling, JP Dumanski, A Guha, V Mautner, M Upadhyaya: High-resolution DNA copy number profiling of malignant peripheral nerve sheath tumors using targeted microarray-based comparative genomic hybridization. Clin Cancer Res 14, 1015-1024 (2008). (Pubitemid 351302546)
12. MA Pujana, JD Han, LM Starita, KN Stevens, M Tewari, JS Ahn, G Rennert, V Moreno, T Kirchhoff, B Gold, V Assmann, WM Elshamy, JF Rual, D Levine, LS Rozek, RS Gelman, KC Gunsalus, RA Greenberg, B Sobhian, N Bertin, K Venkatesan, N Ayivi-Guedehoussou, X Solé, P Hernández, C Lázaro, KL Nathanson, BL Weber, ME Cusick, DE Hill, K Offit, DM Livingston, SB Gruber, JD Parvin, M Vidal: Network modeling links breast cancer susceptibility and centrosome dysfunction. Nat Genet 39, 1338-1349 (2007). (Pubitemid 350035000)
13. J Manning, S Kumar: NEDD1: function in microtubule nucleation, spindle assembly and beyond. Int J Biochem Cell Biol 39, 7-11 (2007). (Pubitemid 44548452)
14. ND Perkins: NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 14, 64-69 (2004).
15. K Damm: ErbA: tumor suppressor turned oncogene? FASEB J 7, 904-909 (1993). (Pubitemid 23225547)
16. C Tolg, SR Hamilton, L Morningstar, J Zhang, S Zhang, KV Esguerra, PG Telmer, LG Luyt, R Harrison, JB McCarthy, EA Turley: RHAMM promotes interphase microtubule instability and mitotic spindle integrity through MEK1/ERK1/2 activity. J Biol Chem 285, 26461- 26474 (2010).
17. V Joukov, AC Groen, T Prokhorova, R Gerson, E White, A Rodriguez, JC Walter, DM Livingston: The BRCA1/BARD1 heterodimer modulates ran-dependent mitotic spindle assembly. Cell 127, 539-552 (2006). (Pubitemid 44647427)
18. S Nagel, P Hirschmann, S Dirnhofer, U Günthert, A Tzankov: Coexpression of CD44 variant isoforms and receptor for hyaluronic acid-mediated motility (RHAMM, CD168) is an International Prognostic Index and C-MYC gene status-independent predictor of poor outcome in diffuse large B-cell lymphomas. Exp Hematol 38, 38-45 (2010).
19. Y Buganim, V Rotter: RHAMM in the complex p53 cell cycle network. Cell Cycle 7, 3287-3291 (2008).
20. S Godar, RA Weinberg: Filling the mosaic of p53 actions: p53 represses RHAMM expression. Cell Cycle 7, 3479 (2008).
21. C Liu, K Kelnar, B Liu, X Chen, T Calhoun-Davis, H Li, L Patrawala, H Yan, C Jeter, S Honorio, JF Wiggins, AG Bader, R Fagin, D Brown, DG Tang: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17, 211-215 (2011).
22. AB D'Assoro, A Leontovich, A Amato, JR Ayers-Ringler, C Quatraro, K Hafner, RB Jenkins, M Libra, J Ingle, F Stivala, E Galanis, JL Salisbury: Abrogation of p53 function leads to metastatic transcriptome networks that typify tumor progression in human breast cancer xenografts. Int J Oncol 37, 1167-1176 (2010).
23. P Auvinen, R Tammi, J Parkkinen, M Tammi, U Agren, R Johansson, P Hirvikoski, M Eskelinen, VM Kosma: Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival. Am J Pathol 156, 529-536 (2000). (Pubitemid 30643808)
24. R Sackstein: The biology of CD44 and HCELL in hematopoiesis: the 'step 2-bypass pathway' and other emerging perspectives. Curr Opin Hematol (2011).
25. D Naor, RV Sionov, D Ish-Shalom: CD44: structure, function, and association with the malignant process. Adv Cancer Res 71, 241-319 (1997). (Pubitemid 27197761)
26. D Naor, S Nedvetzki, I Golan, L Melnik, Y Faitelson: CD44 in cancer. Crit Rev Clin Lab Sci 39, 527-579 (2002). (Pubitemid 35425379)
27. H Ponta, L Sherman, PA Herrlich: CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 4, 33-45 (2003). (Pubitemid 36077255)
28. D Jiang, J Liang, PW Noble: Hyaluronan as an immune regulator in human diseases. Physiol Rev 91, 221-264 (2011).
29. J Lesley, R Hyman, PW Kincade: CD44 and its interaction with extracellular matrix. Adv Immunol 54, 271-335 (1993). (Pubitemid 23289255)
30. J Lesley, R Hyman: CD44 structure and function. Front Biosci 3, d616-630 (1998).
31. DH van Weering, PD Baas, JL Bos: A PCR-based method for the analysis of human CD44 splice products. PCR Methods Appl 3, 100-106 (1993).
32. U Günthert, M Hofmann, W Rudy, S Reber, M Zöller, I Haussmann, S Matzku, A Wenzel, H Ponta, P Herrlich: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65, 13-24 (1991). (Pubitemid 121001209)
33. M Hofmann, W Rudy, M Zöller, C Tölg, H Ponta, P Herrlich, U Günthert: CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. Cancer Res 51, 5292-5297 (1991).
34. S Nedvetzki, I Golan, N Assayag, E Gonen, D Caspi, M Gladnikoff, A Yayon, D Naor: A mutation in a CD44 variant of inflammatory cells enhances the mitogenic interaction of FGF with its receptor. J Clin Invest 111, 1211-1220 (2003). (Pubitemid 36519938)
35. L Eshkar Sebban, D Ronen, D Levartovsky, O Elkayam, D Caspi, S Aamar, H Amital, A Rubinow, I Golan, D Naor, Y Zick, I Golan: The involvement of CD44 and its novel ligand galectin-8 in apoptotic regulation of autoimmune inflammation. J Immunol 179, 1225-1235 (2007).
36. H Yabushita, M Noguchi, T Kishida, K Fusano, Y Noguchi, N Itano, K Kimata, M Noguchi: Hyaluronan synthase expression in ovarian cancer. Oncol Rep 12, 739- 743 (2004).
37. MR Ziebell, GD Prestwich: Interactions of peptide mimics of hyaluronic acid with the receptor for hyaluronan mediated motility (RHAMM). J Comput Aided Mol Des 18, 597-614 (2004). (Pubitemid 40267977)
38. CM Milner, VA Higman AJ Day: TSG-6: a pluripotent inflammatory mediator? Biochem Soc Trans 34, 446-450 (2006). (Pubitemid 43954008)
39. B Yang, BL Yang, RC Savani, EA Turley: Identification of a common hyaluronan binding motif in the hyaluronan binding proteins RHAMM, CD44 and link protein. EMBO J 13, 286-296 (1994). (Pubitemid 24034210)
40. V Orian-Rousseau: CD44, a therapeutic target for metastasising tumours. Eur J Cancer 46, 1271-1277 (2010).
41. XM Xu, Y Chen, J Chen, S Yang, F Gao, CB Underhill, K Creswell, L Zhang: A peptide with three hyaluronan binding motifs inhibits tumor growth and induces apoptosis. Cancer Res 63, 5685-5690 (2003). (Pubitemid 37203377)
42. K Tajima, R Ohashi, Y Sekido, T Hida, T Nara, M Hashimoto, S Iwakami, K Minakata, T Yae, F Takahashi, H Saya, K Takahashi: Osteopontin-mediated enhanced hyaluronan binding induces multidrug resistance in mesothelioma cells. Oncogene 29, 1941-1951 (2010).
43. W Rudy, M Hofmann, R Schwartz-Albiez, M Zöller, KH Heider, H Ponta, P Herrlich: The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior. Cancer Res 53, 1262-1268 (1993). (Pubitemid 23097099)
44. S Seiter, R Arch, S Reber, D Komitowski, M Hofmann, H Ponta, P Herrlich, S Matzku, M Zöller: Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 177, 443-455 (1993). (Pubitemid 23117094)
45. V Orian-Rousseau, L Chen, JP Sleeman, P Herrlich, H Ponta: CD44 is required for two consecutive steps in HGF/c-Met signaling. Genes Dev 16, 3074-3086 (2002). (Pubitemid 35424194)
46. A Matzke, P Herrlich, H Ponta, V Orian-Rousseau: A five-amino-acid peptide blocks Met- and Ron-dependent cell migration. Cancer Res 65, 6105-6110 (2005). (Pubitemid 40994395)
47. V Niggli, J Rossy: Ezrin/radixin/moesin: versatile controllers of signaling molecules and of the cortical cytoskeleton. Int J Biochem Cell Biol 40, 344-349 (2008). (Pubitemid 351241219)
48. V Orian-Rousseau, H Morrison, A Matzke, T Kastilan, G Pace, P Herrlich, H Ponta: Hepatocyte growth factorinduced Ras activation requires ERM proteins linked to both CD44v6 and F-actin. Mol Biol Cell 18, 76-83 (2007). (Pubitemid 46066712)
49. M Tremmel, A Matzke, I Albrecht, AM Laib, V Olaku, K Ballmer-Hofer, G Christofori, M Héroult, HG Augustin, H Ponta, V Orian-Rousseau: A CD44v6 peptide reveals a role of CD44 in VEGFR-2 signaling and angiogenesis. Blood 114, 5236-5244 (2009).
50. C Jung, A Matzke, HH Niemann, C Schwerk, T Tenenbaum, V Orian-Rousseau: Involvement of CD44v6 in InlB-dependent Listeria invasion. Mol Microbiol 72, 1196-1207 (2009).
51. H Riechelmann, A Sauter, W Golze, G Hanft, C Schroen, K Hoermann, T Erhardt, S Gronau: Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma. Oral Oncol 44, 823-829 (2008).
52. M Salmi, K Grön-Virta, P Sointu, R Grenman, H Kalimo, S Jalkanen: Regulated expression of exon v6 containing isoforms of CD44 in man: downregulation during malignant transformation of tumors of squamocellular origin. J Cell Biol 122, 431-442 (1993). (Pubitemid 23210469)
53. S Kikuchi, CT Griffin, SS Wang, DM Bissell: Role of CD44 in epithelial wound repair: migration of rat hepatic stellate cells utilizes hyaluronic acid and CD44v6. J Biol Chem 280, 15398-15404 (2005). (Pubitemid 40562897)
54. D Peck, CM Isacke: Hyaluronan-dependent cell migration can be blocked by a CD44 cytoplasmic domain peptide containing a phosphoserine at position 325. J Cell Sci 111, 1595-1601 (1998). (Pubitemid 28288831)
55. D Derossi, G Chassaing, A Prochiantz: Trojan peptides: the penetratin system for intracellular delivery. Trends Cell Biol 8, 84-87 (1998). (Pubitemid 28056816)
56. B Desai, T Ma, J Zhu, MA Chellaiah: Characterization of the expression of variant and standard CD44 in prostate cancer cells: identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J Cell Biochem 108, 272-284 (2009).
57. MA Chellaiah, RS Biswas, SR Rittling, DT Denhardt, KA Hruska: Rho-dependent Rho kinase activation increases CD44 surface expression and bone resorption in osteoclasts. J Biol Chem 278, 29086-29097 (2003). (Pubitemid 36935823)
58. ME Mummert, M Mohamadzadeh, DI Mummert, N Mizumoto, A Takashima: Development of a peptide inhibitor of hyaluronan-mediated leukocyte trafficking. J Exp Med 192, 769-779 (2000).
59. ME Mummert, D Mummert, D Edelbaum, F Hui, H Matsue, A Takashima: Synthesis and surface expression of hyaluronan by dendritic cells and its potential role in antigen presentation. J Immunol 169, 4322-4331 (2002). (Pubitemid 35178205)
60. JM Zmolik, ME Mummert: Pep-1 as a novel probe for the in situ detection of hyaluronan. J Histochem Cytochem 53, 745-751 (2005). (Pubitemid 40726954)
61. DI Mummert, A Takashima, L Ellinger, ME Mummert: Involvement of hyaluronan in epidermal Langerhans cell maturation and migration in vivo. J Dermatol Sci 33, 91- 97 (2003). (Pubitemid 37315901)
62. Y Morioka, K Yamasaki, D Leung, RL Gallo: Cathelicidin antimicrobial peptides inhibit hyaluronaninduced cytokine release and modulate chronic allergic dermatitis. J Immunol 181, 3915-3922 (2008).
63. DR Fooksman, S Vardhana, G Vasiliver-Shamis, J Liese, DA Blair, J Waite, C Sacristán, GD Victora, A Zanin-Zhorov, ML Dustin: Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol 28, 79-105 (2010).
64. RH Tammi, A Kultti, VM Kosma, R Pirinen, P Auvinen, MI Tammi: Hyaluronan in human tumors: Pathobiological and prognostic messages from cellassociated and stromal hyaluronan. Semin Cancer Biol 18, 288-295 (2008).
65. SR Rudrabhatla, CL Mahaffey, ME Mummert: Tumor microenvironment modulates hyaluronan expression: the lactate effect. J Invest Dermatol 126, 1378-1387 (2006). (Pubitemid 43997922)
66. ME Mummert, DI Mummert, L Ellinger, A Takashima: Functional roles of hyaluronan in B16-F10 melanoma growth and experimental metastasis in mice. Mol Cancer Ther 2, 295-300 (2003).
67. S Twarock, MI Tammi, RC Savani, JW Fischer: Hyaluronan stabilizes focal adhesions, filopodia, and proliferative phenotype in esophageal squamous carcinoma cells. J Biol Chem 285, 23276-23284 (2010).
68. SA Rosenberg, JC Yang, SL Topalian, DJ Schwartzentruber, JS Weber, DR Parkinson, CA Seipp, JH Einhorn, DE White: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using highdose bolus interleukin 2. JAMA 271, 907-913 (1994).
69. R Baluna, ES Vitetta: Vascular leak syndrome: a side effect of immunotherapy. Immunopharmacology 37, 117- 132 (1997). (Pubitemid 27471029)
70. A Mustafa, RJ McKallip, M Fisher, R Duncan, PS Nagarkatti, M Nagarkatti: Regulation of interleukin-2- induced vascular leak syndrome by targeting CD44 using hyaluronic acid and anti-CD44 antibodies. J Immunother 25, 476-488 (2002). (Pubitemid 35266313)
71. RJ McKallip, M Fisher, Y Do, AK Szakal, U Gunthert, PS Nagarkatti, M Nagarkatti: Targeted deletion of CD44v7 exon leads to decreased endothelial cell injury but not tumor cell killing mediated by interleukin-2- activated cytolytic lymphocytes. J Biol Chem 278, 43818- 43830 (2003). (Pubitemid 37346010)
72. H Guan, PS Nagarkatti, M Nagarkatti: Blockade of hyaluronan inhibits IL-2-induced vascular leak syndrome and maintains effectiveness of IL-2 treatment for metastatic melanoma. J Immunol 179, 3715-3723 (2007).
73. V Takafuji, M Forgues, E Unsworth, P Goldsmith, XW Wang: An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26, 6361-6371 (2007). (Pubitemid 47494216)
74. GF Weber: The metastasis gene osteopontin: a candidate target for cancer therapy. Biochim Biophys Acta 1552, 61-85 (2001). (Pubitemid 34124131)
75. E Ruoslahti: RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol 12, 697-715 (1996). (Pubitemid 26422728)
76. S Jalkanen, M Jalkanen: Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol 116, 817-825 (1992).
77. T Yasuda, AR Poole, M Shimizu, T Nakagawa, SM Julovi, H Tamamura, N Fujii, T Nakamura: Involvement of CD44 in induction of matrix metalloproteinases by a COOH-terminal heparinbinding fragment of fibronectin in human articular cartilage in culture. Arthritis Rheum 48, 1271-1280 (2003). (Pubitemid 36554526)
78. S Hibino, M Shibuya, JA Engbring, M Mochizuki, M Nomizu, HK Kleinman. Identification of an active site on the laminin alpha5 chain globular domain that binds to CD44 and inhibits malignancy. Cancer Res 64, 4810-4816 (2004). (Pubitemid 38924524)
79. KL Bennett, DG Jackson, JC Simon, E Tanczos, R Peach, B Modrell, I Stamenkovic, G Plowman, A Aruffo: CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor. J Cell Biol 128, 687-698 (1995).
80. M Jones, L Tussey, N Athanasou, DG Jackson: Heparan sulfate proteoglycan isoforms of the CD44 hyaluronan receptor induced in human inflammatory macrophages can function as paracrine regulators of fibroblast growth factor action. J Biol Chem 275, 7964- 7974 (2000). (Pubitemid 30159706)
81. MR Ziebell, ZG Zhao, B Luo, Y Luo, EA Turley, GD Prestwich: Peptides that mimic glycosaminoglycans: highaffinity ligands for a hyaluronan binding domain. Chem Biol 8, 1081-1094 (2001). (Pubitemid 33119185)
82. AC Groen, LA Cameron, M Coughlin, DT Miyamoto, TJ Mitchison, R Ohi: XRHAMM functions in ran-dependent microtubule nucleation and pole formation during anastral spindle assembly. Curr Biol 14, 1801-1811 (2004). (Pubitemid 39408769)
83. H Merzendorfer: Insect chitin synthases: a review. J Comp Physiol B 176, 1-15 (2006). (Pubitemid 41772259)
84. PL DeAngelis: Hyaluronan synthases: fascinating glycosyltransferases from vertebrates, bacterial pathogens, and algal viruses. Cell Mol Life Sci 56, 670- 682 (1999).
85. CA Maxwell, JJ Keats, M Crainie, X Sun, T Yen, E Shibuya, M Hendzel, G Chan, LM Pilarski: RHAMM is a centrosomal protein that interacts with dynein and maintains spindle pole stability. Mol Biol Cell 14, 2262-2276 (2003). (Pubitemid 36724319)
86. TC Smith, Z Fang, EJ Luna: Novel interactors and a role for supervillin in early cytokinesis. Cytoskeleton (Hoboken) 67, 346-364 (2010).
87. D Manzanares, ME Monzon, RC Savani, M Salathe: Apical oxidative hyaluronan degradation stimulates airway ciliary beating via RHAMM and RON. Am J Respir Cell Mol Biol 37, 160-168 (2007). (Pubitemid 47254999)
88. S Zhang, MC Chang, D Zylka, S Turley, R Harrison, EA Turley: The hyaluronan receptor RHAMM regulates extracellular-regulated kinase. J Biol Chem 273, 11342-11348 (1998). (Pubitemid 28204989)
89. M Slevin, J Krupinski, J Gaffney, S Matou, D West, H Delisser, RC Savani, S Kumar: Hyaluronanmediated angiogenesis in vascular disease: Uncovering RHAMM and CD44 receptor signaling pathways. Matrix Biol 26, 58-68 (2007). (Pubitemid 46091650)
90. S Mohapatra, X Yang, JA Wright, EA Turley, AH Greenberg: Soluble hyaluronan receptor RHAMM induces mitotic arrest by suppressing Cdc2 and cyclin B1 expression. J Exp Med 183, 1663-1668 (1996). (Pubitemid 26134308)
91. S Matou-Nasri, J Gaffney, S Kumar, M Slevin: Oligosaccharides of hyaluronan induce angiogenesis through distinct CD44 and RHAMM-mediated signalling pathways involving Cdc2 and gamma-adducin. Int J Oncol 35, 761-773 (2009).
92. R Silverman-Gavrila, L Silverman-Gavrila, G Hou, M Zhang, M Charlton, MP Bendeck: Rear polarization of the microtubule-organizing center in neointimal smooth muscle cells depends on PKCalpha, ARPC5, and RHAMM. Am J Pathol 178, 895-910 (2011).
93. Y Shen, N Li, S Wu, Y Zhou, Y Shan, Q Zhang, C Ding, Q Yuan, F Zhao, R Zeng, X Zhu: Nudel binds Cdc42GAP to modulate Cdc42 activity at the leading edge of migrating cells. Dev Cell 14, 342-353 (2008).
94. X Yan, F Li, Y Liang, Y Shen, X Zhao, Q Huang, X Zhu: Human Nudel and NudE as regulators of cytoplasmic dynein in poleward protein transport along the mitotic spindle. Mol Cell Biol 23, 1239-1250 (2003). (Pubitemid 36177034)
95. CA Maxwell, E Rasmussen, F Zhan, JJ Keats, S Adamia, E Strachan, M Crainie, R Walker, AR Belch, LM Pilarski, B Barlogie, J Jr Shaughnessy, T Reiman: RHAMM expression and isoform balance predict aggressive disease and poor survival in multiple myeloma. Blood 104, 1151-1158 (2004). (Pubitemid 39038037)
96. V Assmann, D Jenkinson, JF Marshall, IR Hart: The intracellular hyaluronan receptor RHAMM/IHABP interacts with microtubules and actin filaments. J Cell Sci 112, 3943- 3954 (1999). (Pubitemid 30119764)
97. K Giannopoulos, M Schmitt: Targets and strategies for Tcell based vaccines in patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 47, 2028-2036 (2006). (Pubitemid 44650077)
98. C Tolg, R Poon, R Fodde, EA Turley, BA Alman: Genetic deletion of receptor for hyaluronan-mediated motility (Rhamm) attenuates the formation of aggressive fibromatosis (desmoid tumor). Oncogene 22, 6873-6882 (2003). (Pubitemid 37386687)
99. D Jiang, J Liang, PW Noble: Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 23, 435-461 (2007).
100. BM Tijink, J Buter, R de Bree, G Giaccone, MS Lang, A Staab, CR Leemans, GA van Dongen: A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res 12, 6064-6072 (2006). (Pubitemid 44703770)
101. M Bilusic, RA Madan: Therapeutic Cancer Vaccines: The Latest Advancement in Targeted Therapy. Am J Ther (2011).
102. JS Weber: The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies. Melanoma Res 16, 379-383 (2006). (Pubitemid 44511217)
103. F Saleh, W Renno, I Klepacek, G Ibrahim, S Asfar, H Dashti, P Romero, A Dashti, A Behbehani: Melanoma immunotherapy: past, present, and future. Curr Pharm Des 11, 3461-3473 (2005). (Pubitemid 41300753)
104. SY Lee, D Jeoung: The reverse proteomics for identification of tumor antigens. J Microbiol Biotechnol 17, 879-890 (2007). (Pubitemid 47162050)
105. Y Wang, Q Gu, B Liu, Z Zhu: Perspectives of SEREX-defined antigens in diagnosis and immunotherapy for gastric cancer. Cancer Biol Ther 3, 806-811 (2004). (Pubitemid 41351041)
106. BJ Bergin, SW Pierce, LR Bramlage, A Stromberg: Oral hyaluronan gel reduces post operative tarsocrural effusion in the yearling Thoroughbred. Equine Vet J 38, 375-378 (2006). (Pubitemid 44440873)
107. J Greiner, M Ringhoffer, M Taniguchi, A Schmitt, D Kirchner, G Krähn, V Heilmann, J Gschwend, L Bergmann, H Döhner, M Schmitt: Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia. Exp Hematol 30, 1029-1035 (2002). (Pubitemid 35286619)
108. C Wang, AD Thor, DH 2nd Moore, Y Zhao, R Kerschmann, R Stern, PH Watson, EA Turley: The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression. Clin Cancer Res 4, 567-576 (1998). (Pubitemid 28193554)
109. I Zlobec, K Baker, L Terracciano, S Peter, L Degen, C Beglinger, A Lugli: Two-marker protein profile predicts poor prognosis in patients with early rectal cancer. Br J Cancer 99, 1712-1717 (2008).
110. E Karamitopoulou, A Lugli, I Panayiotides, P Karakitsos, G Peros, G Rallis, ES Patsouris, L Terracciano, I Zlobec: Systematic assessment of protein phenotypes characterizing high-grade tumour budding in mismatch repair-proficient colorectal cancer. Histopathology 57, 233-243 (2010).
111. K Giannopoulos, D Mertens, A Bühler, TF Barth, I Idler, P Möller, A Kröber, J Greiner, S Chocholska, A Dmoszyñska, J Roliñski, H Döhner, S Stilgenbauer, M Schmitt: The candidate immunotherapeutical target, the receptor for hyaluronic acid-mediated motility, is associated with proliferation and shows prognostic value in B-cell chronic lymphocytic leukemia. Leukemia 23, 519-527 (2009).
112. T Tzellos, A Kyrgidis, K Vahtsevanos, S Triaridis, A Printza, I Klagas, E Zvintzou, A Kritis, G Karakiulakis, E Papakonstantinou: Nodular basal cell carcinoma is Acad Dermatol Venereol 25, 679-687 (2010).
113. A Burnett, M Wetzler, B Lowenberg: Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29, 487-494 (2011).
114. MM van Luijn, W van den Ancker, ME Chamuleau, GJ Ossenkoppele, SM van Ham, AA van de Loosdrecht: Impaired antigen presentation in neoplasia: basic mechanisms and implications for acute myeloid leukemia. Immunotherapy 2, 85-97 (2010).
115. M Schmitt, R Casalegno-Garduño, X Xu, A Schmitt: Peptide vaccines for patients with acute myeloid leukemia. Expert Rev Vaccines 8, 1415-1425 (2009).
116. J Greiner, A Schmitt, K Giannopoulos, MT Rojewski, M Götz, I Funk, M Ringhoffer, D Bunjes, S Hofmann, G Ritter, H Döhner, M Schmit: High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 95, 1191-1197 (2010).
117. K Giannopoulos, A Dmoszynska, M Kowal, J Rolinski, E Gostick, DA Price, J Greiner, M Rojewski, S Stilgenbauer, H Döhner, M Schmitt: Peptide vaccination elicits leukemia-associated antigen-specific cytotoxic CD8+ T-cell responses in patients with chronic lymphocytic leukemia. Leukemia 24, 798-805 (2010).
118. HS Yang, DM Zhang, HX Deng, F Peng, YQ Wei: Antitumor and anti-angiogenesis immunity induced by CR-SEREX-identified Xenopus RHAMM. Cancer Sci 101, 862-868 (2010).
119. T Amano, K Kajiwara, K Yoshikawa, J Morioka, S Nomura, H Fujisawa, S Kato, M Fujii, M Fukui, Y Hinoda, M Suzuki: Antitumor effects of vaccination with dendritic cells transfected with modified receptor for hyaluronan-mediated motility mRNA in a mouse glioma model. J Neurosurg 106, 638-645 (2007). (Pubitemid 46536461)
120. RC Savani, N Khalil, EA Turley: Hyaluronan receptor antagonists alter skin inflammation and fibrosis following injury. Proc West Pharmacol Soc 38, 131-136 (1995).
121. CS Tolg, RC, L Luyt, M Cowman, JB McCarthy, EA Turley: RHAMM mimetic peptides reduce tissue scarring. submitted, (2011).
122. HN 3rd Lovvorn, DL Cass, KG Sylvester, EY Yang, TM Crombleholme, NS Adzick, RC Savani: Hyaluronan receptor expression increases in fetal excisional skin wounds and correlates with fibroplasia. J Pediatr Surg 33, 1062-1069; discussion 1069-1070 (1998).
123. KJ Zaleski, T Kolodka, C Cywes-Bentley, RM McLoughlin, ML Delaney, BT Charlton, W Johnson, AO Tzianabos: Hyaluronic acid binding peptides prevent experimental staphylococcal wound infection. Antimicrob Agents Chemother 50, 3856-3860 (2006). (Pubitemid 44684903)
124. JC Lee, JL Greenwich, GG Zhanel, X Han, A Cumming, L Saward, RM McLoughlin: Modulation of the local neutrophil response by a novel hyaluronic acidbinding peptide reduces bacterial burden during staphylococcal wound infection. Infect Immun 78, 4176- 4186 (2010).
125. RC Savani, G Hou, P Liu, C Wang, E Simons, PC Grimm, R Stern, AH Greenberg, HM DeLisser, N Khalil: A role for hyaluronan in macrophage accumulation and collagen deposition after bleomycin-induced lung injury. Am J Respir Cell Mol Biol 23, 475-484 (2000).
126. K Amemiya, T Nakatani, A Saito, A Suzuki, H Munakata: Hyaluronan-binding motif identified by panning a random peptide display library. Biochim Biophys Acta 1724, 94-99 (2005). (Pubitemid 40799114)